$SGMT
Sagimet Biosciences Inc. Series A Common Stock
XNAS
Why is SGMT up today? It is at $8.74 (+1.16%), and our scanner flagged it 22 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment SGMT spikes, and full due diligence on SGMT — key stats, earnings, dilution and insider activity. Free.
Get free $SGMT alerts the moment volume spikes
Our scanner flagged $SGMT 22 times in the last 30 days. Create a free account to track $SGMT, build a watchlist, and get instant unusual-volume alerts — plus 5 free premium days, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $8.74
- Change today
- +1.16%
- Previous close
- $8.64
- 52-week range
- $4.50 – $10.06
- Market cap
- $265M
- Institutional own.
- 25.53%
- Total held
- 38.9%
- Tradeable float
- 18.7M 61% of shares · after 13% insiders + 26% institutions
- Short interest
- 9.7M ▲ +18% vs prior · as of 2026-07-15
- Short % of float
- 52.0%
- Days to cover
- 9.2d
- Avg daily volume
- 917K
- Exchange
- XNAS
- 5m
- 0.6x
- 15m
- 0.9x
- 1h
- 1.1x
- 1D
- 0.4x
Get free SGMT + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $SGMT up today?
Here is the latest on SGMT from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for SGMT today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystTargeting Metabolic Dysfunction with Novel TherapeuticsReported Our follow-on FASN inhibitor, TVB 3567, received Investigational New Drug (IND) clearance in March 2025 • First-in-human (FIH) Phase 1 clinical trial initiated in June 2025 for development of an acne indication TVB-3567 in Acne •Reported Intralesional corticosteroids • Salicylic Acid • Azelaic Acid Potential treatment positioning for FASN inhibitors Oral FASN Inhibitor Topical FASN Inhibitor Source: https://www.jaad.org/article/S0190-9622(23)03389-3/fulltext JulyReported Plan to complete all development and regulatory activities needed for denifanstat-resmetirom combination Phase 2 readiness by end of 2026 • Further MASH development to be undertaken only upon securing non-dilutive funding July 2026, from the latest SEC filing. Read it →Insiders
Insiders selling0 buys, 3 sells last 3 months (5/8 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Kemble George Director | Sold (automatic/other) | -19K 0.06% of company | sold 23% | 62K | $141K at $7.46 | Jul 20, 26 |
Rozek Elizabeth Officer | Sold (automatic/other) | -11K 0.03% of company | sold 4.5% | 224K | $82K at $7.76 | Jul 20, 26 |
Happel David Officer | Sold (automatic/other) | -64K 0.2% of company | sold 8.0% | 742K | $497K at $7.76 | Jul 20, 26 |
Chauche Thierry Officer | Acquired (grant/award) | +44K 0.1% of company | added 100% | 60K | n/a | Feb 19, 26 |
Happel David Officer | Acquired (grant/award) | +128K 0.4% of company | added 19% | 806K | n/a | Feb 19, 26 |
Martins Eduardo Bruno Officer | Acquired (grant/award) | +44K 0.1% of company | added 43% | 147K | n/a | Feb 19, 26 |
Rozek Elizabeth Officer | Acquired (grant/award) | +44K 0.1% of company | added 23% | 235K | n/a | Feb 19, 26 |
Rozek Elizabeth Officer | Sold (automatic/other) | -3K | sold 1.4% | 191K | $14K at $5.36 | Feb 10, 26 |
Martins Eduardo Bruno Officer | Sold (automatic/other) | -4K 0.01% of company | sold 3.4% | 103K | $20K at $5.36 | Feb 10, 26 |
Chauche Thierry Officer | Sold (automatic/other) | -1K | sold 7.7% | 16K | $7K at $5.36 | Feb 10, 26 |
Happel David Officer | Sold (automatic/other) | -12K 0.04% of company | sold 1.8% | 678K | $65K at $5.36 | Feb 10, 26 |
Kemble George Officer | Sold (automatic/other) | -38K 0.1% of company | sold 32% | 81K | $290K at $7.69 | Nov 20, 25 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Recent offeringAt-the-market (ATM) offering active — the company can keep selling new shares into the market over time (ongoing). If $SGMT runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
- At-the-market (ATM) program — sells new shares into the market gradually over time
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$SGMT Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$SGMT Activity
News, unusual-volume alerts, AI-trader trades and community chatter — the whole story, newest first.
SGMT stock FAQ
Why is $SGMT up today?
Here is the latest on SGMT from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for SGMT today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
What is the SGMT stock price today?
SGMT last traded at $8.74, up 1.16% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live SGMT alerts?
The SGMT Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged SGMT 22 times in the last 30 days.
What exchange is SGMT on?
SGMT (Sagimet Biosciences Inc. Series A Common Stock) trades on XNAS, with a market cap of about $265M.
Is SGMT good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge SGMT for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.